Abstract: Aqueous guar gum compositions having a very low content of insolubles, the compositions being formed by impregnating free-flowing solid, particulate guar gum with one or more hydrolytic enzymes and thereafter dissolving the particles of guar gum in water.

Abstract: A reactor 10 for cultivating biological material is colonized with plant cells 3 in channels 2a of a support matrix. The biological material cannot pass out of the channels. Each colonized channel adjoins several non-colonized channels 2, viz. a nutrient supply channel, an extractant channel, a heat-transfer channel and a gas supply channel. The walls separating the different pairs of these channels are permeable to the relevant material only.

Abstract: An apparatus for sequentially fractionating a centrifuge tube includes a capillary tube and a means for applying positive pressure. The capillary tube has an O-ring at the lower end thereof. As the capillary tube is placed within the centrifuge tube, the O-ring forms a seal within the tube. Movement of the capillary tube within the centrifuge tube places the liquid in the centrifuge tube under pressure, thus forcing the liquid to flow up through the capillary tube and into a chamber. A chase fluid is then pumped horizontally through the chamber to force the liquid therein through an exit port and into a fraction collector. The apparatus and method of the present invention may be entirely automated and controlled by a single microprocessor.

Abstract: A chemically active membrane having a large surface area is provided in which a hydrophilic, microporous, skinless, polyamide membrane is chemically bound to a residue of an activating agent which is capable of reacting with a biologically active material.The chemically active membrane, formed by reacting a hydrophilic, microporous, skinless, polyamide membrane with an activating agent may be used to prepare a biologically active membrane having a large surface area which comprises an acceptor molecule such as a monoclonal antibody, a polyclonal antibody, an antigenic substance, a glycoprotein, Protein A, a lectin, a carbohydrate, an enzyme substrate, a cofactor, an inhibitor, a hormone, an IgG class of immunoglobulin, a carrier protein, a receptor, heparin, a coagulation factor, or a histone covalently bound to the hydrophilic, microporous, skinless, polyamide membrane by reacting the chemically activate membrane with the acceptor molecule.

Abstract: The invention disclosed by this application relates to a novel method of processing sinterable powders into sintered ceramic products. This application also relates to novel forms of aluminum oxide, hydroxylapatite, and tricalcium phosphate ceramic products prepared in accordance with the method of this invention, as well as novel intermediate products useful to prepare the novel ceramic products of this invention.

Abstract: This invention relates to glass compositions especially designed for use as envelopes for tungsten-halogen incandescent lamps wherein molybdenum metal lead wires are utilized. The glasses consist essentially, expressed in terms of weight percent on the oxide basis, of 8.5-14% BaO, 10.5-12.5% CaO, 14-15.5% Al.sub.2 O.sub.3, and 59.5-63% SiO.sub.2.

Abstract: The present invention provides a method of pressureless sintering silicon carbide in which the silicon carbide starting material is in the form of a multimodal composition, or mixture, of coarse and submicron particles. The present sinterable silicon carbide mixtures consist of separate fractions of sized particles. Each fraction is present in amounts of from about 5 to about 75% by weight of the mixture, and more preferably from about 10 to about 65% by weight of the mixture. One fraction has a particle size ranging between about 0.21 mm (210 microns) to about 3.4 mm (3400 microns) and preferably the larger particles have a size less than about 2.4 mm. A second fraction has a particle size ranging between about 0.003 mm (3 microns) up to about 0.21 mm. A third fraction has a size less than 0.003 mm, but has an average size less than 1 micron. The present products are produced by sintering particulate silicon carbide in the presence of a sintering aid and a slight excess carbon.

Abstract: The invention relates to the production of desirably consolidated high purity refractory metal borides, carbides, nitrides, or mixtures, combinations of cermets thereof. In the preparation, a second stage reaction is conducted at reduced pressure and sintering temperature. Furthermore, it is carried out in the presence of sintering aid which can be initially present as a particulate material and, as such, may be incorporated with other reaction ingredients. Sintering aid, in a dual role, may serve not only as an assistant in the second stage reaction, but also as a reaction participant. Moreover, during such rection at sintering conditions, the sintering assistance is obtained by means of sintering aid vapor. High purity products of desirable microstructure can be achieved, having densities on the order of 90 percent or more.

Abstract: A titamium containing catalyst component for olefin polymerizations which comprises contacting (a) a metal oxide, (b) a dihydrocarbyl magnesium, and (c) a hydrocarbyloxy group-containing compound with one another, contacting the thus obtained contact product with (d) a halogen-containing alcohol, and finally contacting the thus obtained contact product with (e) an electron donor compound and (f) a titanium compound.

Abstract: A catalyst composition comprises (a) alumina, (b) zinc titanate, (c) at least one compound of molybdenum, (d) at least one compound of at least one of nickel and cobalt, and (e) at least one compound of rhenium. This catalyst composition is used for hydrotreating a liquid hydrocarbon-containing feed stream, which contains organic compounds of sulfur, nitrogen and oxygen under such conditions as to obtain a product having reduced levels of sulfur, nitrogen and oxygen. Preferably the hydrocarbon-containing feed stream contains cycloalkanes, which are at least partially reformed to aromatic compounds.

Abstract: Antibiotic-metal complexes contain bacitracin, a non-toxic, complex-forming metal and a polyether antibiotic are disclosed. The complexes are useful (1) for promoting growth in poultry and mammals, (2) for controlling swine dysentery, (3) modifying rumen fluid by decreasing the acetate to propionate (A/P) ratio, (4) controlling coccidiosis in birds, and (5) purifying bacitracin or a bacitracin-metal salt.

Abstract: The substitution of the L-Pro at the 7-position of the peptide hormone bradykinin or other substituted analogs of bradykinin with an aromatic amino acid or the D-configuration converts bradykinin agonists into a bradykinin antagonist. The invention further includes additional modifications at other positions within the novel 7-position modified bradykinin antagonists which increase enzyme resistance, antagonist potency and/or specificity of the new bradykinin antagonists. The analogs produced are useful in treating conditions and diseases of the mammal and human body in which an excess of bradykinin or related kinins are produced or injected as by bites into the body.

Abstract: The present invention discloses a synthetic peptide capable of inducing antibodies protective against human malarial infection caused by Plasmodium vivax sporozoites and the cloning of a gene encoding said peptide. The amino acid and nucleotide sequences of the peptide and the gene, respectively, have been determined and described.

Abstract: Defibrotide, a polydeoxyribonucleotide, obtained by extraction from animal organs, is the active ingredient of compositions for the treatment of acute states of myocardial ischemia and infarction.

Abstract: The present invention relates to a combination of selected cardiotonic agents with selected adenosine receptor agonist antihypertensive agents resulting in a synergistic increase in myocardial contractility and cardiac output thereby rendering such combinations useful in treating heart failure.

Abstract: A novel complex of carrageenan and a member of the group consisting of emepronium, doxycycline, and propranolol, pharmaceutical preparations containing such a complex, and its use in medicine.

Abstract: The compounds have the structure 2-(2-amino or alkyl-amido-2-desoxy-3-O-D-glucopyranosyl)-alkanyl-dipeptide, possibly substituted on the saccharide residue the amino acid residue at the end of the peptide chain being a D-glutamyl residue whose .alpha.-carboxy function is esterified and .gamma.-carboxyl function amidated. The compounds are valuable as immunological medicaments.

Abstract: Pharmaceutical composition for administration primarily to the respiratory tract when treating and controlling anti-inflammatory conditions comprising liposomes in combination with a compound of the formula ##STR1## and R.sup.1 is a saturated or unsaturated, straight or branched alkyl group with 11-19 carbon atoms and R is H, --COCH.sub.3, --COC.sub.2 H.sub.5, --CO(CH.sub.2).sub.2 CH.sub.3 or --CO(CH.sub.2).sub.3 CH.sub.3.The invention also refers to the compounds of the formula I per se processes for preparation of these compounds and to a method for the treatment of inflammatory conditions.

Abstract: The invention relates to novel quinazoline and isoquinoline derivatives of the general formula: ##STR1## and acid addition salts and copper complexes thereof, wherein X represents nitrogen or a CH group,Y represents oxygen or an NH group,R.sub.1 and R.sub.2 represent hydrogen, alkyl(1-6 C), alkoxy (1-6 C), halogen or trifluoromethyl,R.sub.3 represents a substituted or unsubstituted 2-pyridyl group andR.sub.4 represents hydrogen, an alkyl(1-6 C) group unsubstituted or substituted by halogen, alkoxy (1-6 C) or phenyl groups, a cyclic alkyl group or a substituted or unsubstituted aromatic group.

Abstract: .beta.-Lactam compounds represented by the general formula: ##STR1## (wherein X represents CH.sub.2, S or O; Y represents a hydroxyl group, a lower alkanoyloxy group or a lower alkoxycarbonyloxy group; W is a group represented by CH.sub.2, NH, ##STR2## A is a phenyl group, a naphthyl group, or a monocyclic or dicyclic heterocyclic group, respectively substituted by (Y).sub.n ; R.sub.4 and R.sub.5 each are a hydrogen atom, a lower alkyl group, or a cycloalkylidene group with a carbon atom combined therewith; l is 0 or an integer of 1, 2 or 3; m is 0 or 1; n is an integer of 1, 2, 3, 4 or 5; and R.sub.1, R.sub.2 and R.sub.3 are groups often used in the conventional .beta.-lactam compounds) have strong antimicrobial activities against a wide range of Gram positive and negative bacteria; particularly Gram negative bacteria including Pseudomonas aeruginosa, Pseudomonas sepatia and various Enterobacters.

Abstract: Calcium channel blocking activity is exhibited by compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein the stereochemistry at the chiral centers in the 3 and 4-positions of the benzothiazepine nucleus is cis, and whereinR.sub.1 is alkyl, aryl, arylalkyl, alkenyl or alkynyl;R.sub.2 and R.sub.5 are each independently hydrogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, halogen or trifluoromethyl; andR.sub.3 and R.sub.4 are each independently alkyl or cycloalkyl or R.sub.3 and R.sub.4 together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl or morpholinyl.

Abstract: A method of treating depression with 5-(aminoalkyl)-11-phenyl-5H-dibenzo[b,e][1,4]diazepines having the formula: ##STR1## wherein R.sup.1 and R.sup.2 are selected from hydrogen or methyl and X is selected from hydrogen, chlorine, bromine or fluorine is disclosed.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1 is hydrogen,R.sup.2 is hydrogen, lower alkyl, ar(lower)alkyl, lower alkenyl or aryl,R.sup.3 is lower alkyl, ar(lower)alkyl, lower alkenyl or aryl, orR.sup.2 and R.sup.3 are taken together to form (C.sub.2 -C.sub.6)-alkylidene group optionally substituted with aryl or taken together with the attached nitrogen atom to form a saturated or unsaturated, 5- or 6-membered heterocyclic group optionally substituted with aryl or lower alkyl; orR.sup.1 and R.sup.2 are taken together with the attached nitrogen atoms to form a saturated or unsaturated, 5- or 6-membered heterocyclic group or 1,2-diazaspiroalkane-1,2-diyl group,R.sup.3 is hydrogen, lower alkyl, ar(lower)alkyl, lower alkenyl or aryl;R.sup.4 is lower alkyl optionally substituted with di(lower)alkylamino or a heterocyclic group, or a heterocyclic group optionally having suitable substituent(s),R.sup.

Abstract: Heterocyclic compounds of the formula ##STR1## wherein either X is --CR.sup.1 R.sup.2 and Y is --O--, --S-- or --NR.sup.3 --, wherein R.sup.1, R.sup.2 and R.sup.3, which may be the same or different, each is hydrogen or alkyl of up to 4 carbon atoms;or X is --O--, --S-- or --NH-- and Y is --CR.sup.1 R.sup.2 -- wherein R.sup.1 and R.sup.2 have the meanings stated above;wherein either R.sup.4 is hydrogen, fluoro or chloro, or alkyl, alkenyl, halogenoalkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or alkoxy each of up to 6 carbon atom, and R.sup.5, R.sup.6 and R.sup.7, which may be the same or different, each is hydrogen, fluoro, chloro, bromo or iodo, or alkyl, alkenyl, halogenoalkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or alkoxy each of up to 6 carbon atoms, provided that R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are not all hydrogen;or R.sup.4 is bromo and R.sup.5, R.sup.6 and R.sup.7 have the meanings stated above, provided that R.sup.5, R.sup.6 and R.sup.7 are not all hydrogen;or R.sup.4 and R.sup.

Abstract: Compounds of the formula Ia and Ib ##STR1## are prodrugs of allopurinol and have i.a. a much higher solubility in water and/or a higher lipophilicity than allopurinol, which makes such compounds useful for oral, parenteral and rectal administration to a warm-blooded animal such as a human. Such compounds will after administration be converted into allopurinol.

Abstract: A method of treating infections of Toxoplasmosis or P. carini comprising administering to the host an effective amount of trimetrexate, (2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline.

Abstract: This invention relates to 5-oxypyrimidinone compounds having H.sub.2 -antagonist activity. A particular compound of the invention is 2-[3-(3-piperidinomethyl)phenoxy)propyl]-5-benzyloxypyrimidin-4-one.

Abstract: The invention discloses novel N-(2-nitrophenyl)-2-aminopyrimidine derivatives of the general formula I ##STR1## wherein R.sub.1 and R.sub.2 are hydrogen, NO.sub.2 or CF.sub.3, with the proviso that only R.sub.1 or R.sub.2 can be NO.sub.2 ;R.sub.4 is hydrogen or the --C(O)R' group, in which R' is C.sub.1 -C.sub.4 alkyl which is unsubstituted or substituted by halogen, C.sub.1 -C.sub.3 alkoxy or C.sub.1 -C.sub.3 alkylthio;R.sub.5, R.sub.6 and R.sub.7 are each independently halogen, nitro, cyano, thiocyano, C.sub.1 -C.sub.12 alkyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.1 -C.sub.8 alkylthio, C.sub.1 -C.sub.6 alkylsulfonyl, C.sub.1 -C.sub.6 alkylsulfoxyl, C.sub.3 -C.sub.6 alkenyl, C.sub.3 -C.sub.6 haloalkenyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.6 haloalkynyl, C.sub.3 -C.sub.6 alkenyloxy, C.sub.3 -C.sub.6 haloalkenyloxy, C.sub.3 -C.sub.6 alkenylthio, C.sub.3 -C.sub.6 alkynyloxy, C.sub.3 -C.sub.6 haloalkynyloxy, C.sub.1 -C.sub.8 alkyl which is substituted by halogen, cyano and/or C.sub.1 -C.sub.

Abstract: Diphenylhydantoin and for dextromethorphan to control seizures.

Abstract: Novel 7-hydroxy-indoles of the formula ##STR1## wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 5 carbon atoms, cycloalkylalkyl of 4 to 7 carbon atoms and aralkyl of 7 to 12 carbon atoms optionally substituted by one or more members of the group consisting of alkyl and alkoxy of 1 to 5 carbon atoms, halogen and alkenyl and alkynyl of 3 to 5 carbon atoms with the multiple bond being other than between the carbons .alpha.- and .beta.- to the nitrogen atom, R.sub.1 is selected from the group consisting of --OH, alkoxy of 1 to 5 carbon atoms, phenoxy and phenylalkoxy of 7 to 9 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts having remarkable dopaminergic properties with few central effects and a novel process and novel intermediates for their preparation.

Abstract: This invention concerns a method of treatment using 1,4-dihydropyridine derivatives having the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R is aryl or heteroaryl;R.sup.1 and R.sup.2 are each independently C.sub.1 -C.sub.4 alkyl or 2-methoxyethyl;Y is --(CH.sub.2).sub.n --, --CH.sub.2 CH(CH.sub.3)-- or --CH.sub.2 C(CH.sub.3).sub.2 --;X is a 5 or 6 membered nitrogen containing aromatic heterocyclic ring which may optionally be substituted by one or more C.sub.1 -C.sub.4 alkyl, phenyl, benzyl, CN, --N(R.sup.3).sub.2, (CH.sub.2).sub.m CO.sub.2 H, (CH.sub.2).sub.m CO.sub.2 (C.sub.1 -C.sub.4 alkyl) or (CH.sub.2).sub.m CON(R.sup.3).sub.2 groups wherein each R.sup.3 is independently H or C.sub.1 -C.sub.4 alkyl and m is 0 or 1;and n is 1 to 3 when X is linked by a ring carbon atom or 2 or 3 when X is linked by a ring nitrogen atom.

Abstract: Insecticidal and acaricidal organic esters formed from pyrethroid carboxylic acids and phenoxypyridinyltrifluoroethanols, agricultural compositions containing said esters and their use against anthropod pests including soil-dwelling species; also, intermediates for these insecticides and acaricides and a process for the preparation of said intermediates.

Abstract: The invention relates to novel compounds of the formulae ##STR1## in which formulae R'is C.sub.1 -C.sub.5 alkyl, C.sub.1 -C.sub.5 alkoxy, halogen or trifluoromethyl,R" is C.sub.1 -C.sub.5 alkyl or halogen,m is 1 ot 3 and n is 0 to 1,X is oxygen or sulfur,Y is hydrogen, fluorine, trifluoromethyl or the group HC(F)Z,Y' is hydrogen or the group CHF.sub.2 andZ is fluorine or trifluoromethyl,as active ingredients for controlling nematodes which parasitise on plants and for protecting cultivated plants from damage caused by nematode attack.

Abstract: The invention relates to pharmaceutical or veterinary compositions for initing the malformation or destruction of red blood corpuscules due to a genetic modification of haemoglobin or to parasites, compositions comprising, as active ingredient, at least one thiosulfonate derivative of general formula:R--S--SO.sub.2 --R.sub.1in which R represents a 1-methyl-imidazol-2-yl, 1H-benzimidazol-2-yl or benzoxazol-2-yl radical and R.sub.1 represents a lower alkyl, (hydroxy) lower alkyl, lower alkanoyl, phenyl, (lower alkyl) phenyl, (hydroxy lower alkyl) phenyl, (lower alkanoyl) phenyl or quinolin-8-yl radical.The compositions in question can be used in the treatment of drepanocytosis, malaria and babebiosis.

Abstract: Novel phthalamide compounds are disclosed having activity against a broad spectrum of parasitic worms and showing no toxicity to the host animal. These compounds are N-(3-chloro-4,5-dihydroisoxazol-4-yl)-N'-(substituted)phthalamides. A process for making these compounds and a method of administering them to animals are also disclosed.

Abstract: Novel oxindole derivative and salt thereof represented by the general formula, ##STR1## wherein R.sup.1 is a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group or a phenyl-lower alkyl group; R.sup.2 is a hydrogen atom or a lower alkyl group; R.sup.3 is a hydrogen atom, a cycloalkylcarbonyl group, a benzoyl group which may have 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group and a lower alkoxy group on the phenyl ring, or a phenyl-lower alkanoyl group which may have halogen atoms as the substituents on the phenyl ring; provided that when R.sup.4 is a hydrogen atom, then R.sup.3 should be neither a hydrogen atom nor a lower alkyl group.The novel oxindole derivative and salt thereof possesses anti-peptic ulcer effects and are useful as anti-peptic ulcer agents.

Abstract: The compounds of the present invention comprise substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives thereof represented by the formula: ##STR1## wherein: R represents hydroxy, alkoxy of from 1 to 6 carbon atoms, inclusive, or amino; R.sup.1 represents hydrogen or acyl of from 2 to 7 carbon atoms, inclusive; and X represents hydrogen, halogen, hydroxy or alkoxy of from 1 to 6 carbon atoms, inclusive. The compounds of the present invention are 5-lipoxygenase inhibitors and, therefore, are useful in the treatment of local and systemic inflammation, allergy and hypersensitivity reactions and other disorders in which agents formed in the 5-lipoxygenase metabolic pathway are involved.

Abstract: The present invention relates to therapeutic compositions for the treatment of gastric disorders, said compositions containing a compound of the formula ##STR1## in which R is a mono- or poly-cyclic heterocyclic radical, possibly substituted, containing an oxygen atom, R' is a hydrogen atom or a linear, branched or cyclic alkyl radical, saturated or unsaturated, containing up to 18 carbon atoms, and,either A represents a hydrogen atom and B represents a hydroxyl radicalor A and B together form a carbon-carbon double bond, as well as the pharmaceutically acceptable alkaline, alkaline-earth or amine salts thereof.

Abstract: Derivatives of 2-(substituted sulfamyl) 6-nitrobenzoic acids are disclosed, wherein at least one of the sulfamyl substituents is selected from amino-(lower alkyl), (lower alkyl)-amino-(lower alkyl), or di(lower alkyl)-amino-(lower alkyl), hydrogen, lower alkyl, hydroxy-(lower alkyl), allyl, or when taken together with the nitrogen of the sulfamyl moiety, form a heterocyclic ring. These compounds have activity in increasing the sensitivity of hypoxic tumor cells to therapeutic radiation. Also disclosed are methods of preparing such compounds and pharmaceutical compositions including such compounds.

Abstract: Topical application to regions of tissue scarring of a composition comprised of several ingredients commonly used in cosmetic products, such as urea, leads to a reduction and a softening of scar tissue.

Abstract: Fatty acid salts of betaxolol, a cardioselective beta-blocker, and ophthalmic compositions containing these salts are described. These new salts have an aqueous solubility significantly less than that of betaxolol hydrochloride. This relatively poor aqueous solubility enables the salts to be slowly released from a suitable ophthalmic vehicle when placed in the aqueous environment of the eye. The salts also exhibit a significantly lower incidence of ocular irritation, as compared to ophthalmic solutions containing betaxolol hydrochloride.

Abstract: Polyolefinic compounds represented by the general formula ##STR1## in which R and R.sub.1 are each hydrogen or an alkyl group of from 1 to 5 carbon atoms; R.sub.2 is an alkyl group of from 1 to 5 carbon atoms; R.sub.3 is hydroxyl, alkoxy of from 1 to 5 carbon atoms, NH.sub.2, NHR.sub.2 or NR.sub.2 R.sub.2 and Z is a cycloalkyl, cycloalkenyl or cycloalkdienyl group substituted with from 0 to 5 alkyl groups, a keto group or a hydroxyl group or a phenyl group substituted with from 0 to 4 hydroxy, alkoxy, alkyl or trifluoromethyl groups or halogen atoms or combinations thereof and the pharmaceutically-acceptable salts thereof.The foregoing compounds have been found to be effective in the treatment of psoriasis, inflammatory conditions and allergic responses.

Abstract: O-acetylsalicylic acid and a pyrimido-pyrimidine as combination products.

Abstract: An expandable ethylenic or styrenic polymer composition for production of lightly crosslinked foamed polymers and a process for controlling the degree of crosslinking of the polymer prior to extrusion foaming. The control is obtained by use of (a) a reversible gas-yielding crosslinking reaction which is delayed in the foam extrusion line in the presence of gaseous products (alcohols) and (b) added amounts of an alcohol such as an aliphatic alcohol. Suitable crosslinking agents include silanes, azido functional silanes, titanates, and amino compounds.

Abstract: A process for dimensionally stabilizing low density foamed polyolefins utilizing a dimensionally stabilizing control additive comprising a nitrogen-containing compound (having an unsaturated leg) said compound represented by formulas (I) and (II): ##STR1##

Abstract: An expandable polyolefin composition and a method of preparation are provided. Isobutane or mixtures of isobutane with other physical blowing agents are utilized to expand polyolefin compositions which have been modified by the addition of a stability control agent. The composition has a high degree of dimensional stability and exhibits minimal shrinkage during curing and/or aging.

Abstract: This invention is concerned with a method for producing phenol resin foam possessing a compact cellular structure, a high closed cell ratio and improved heat resistance. The method consists of using a resole type phenolic resin having a number average molecular weight of 150-400, surface active agents, blowing agents and curing agents, wherein at least two surface active agents are chosen from general formulas A and B, but a selection of each type must be employed ##STR1## where R.sub.1 is a saturated aliphatic hydrocarbon group of 8-14 carbon atoms and/or a 2-phenylpropyl group, and m and n are integers and meet the requirement: ##EQU1## R.sub.2 is a saturated aliphatic hydrocarbon group of 4-12 carbon atoms, M is a hydrogen atom or SO.sub.2 Na, and x is an integer of 4-110.

Abstract: A photopolymerizable composition comprises a polymerizable epoxy-containing material, a polymerizable monomer or monomers containing one or more ##STR1## groups wherein R is H or CH.sub.3, a cationic photoinitiator, a radical-type photoinitiator and an alcohol accelerator.

Abstract: The present invention relates to intumescent polysiloxane molding compositions containing expandable graphite compounds and, if appropriate, additionally nitrogen-containing phosphates.

Abstract: Disclosed is a glass fiber-reinforced composition, which comprises (A) 99-40 wt. % of a modified ethylene/propylene block copolymer having a polar monomer content of at least 0.05 wt. %, which is obtained by graft-modifying at least partially a crystalline ethylene/propylene block copolymer, in which the ethylene content is 3-15 wt. %, the melt flow rate is 0.1 to 70 g/10 min, the intrinsic viscosity of the portion soluble in p-xylene at normal temperature is 2.5-6 as measured in decalin at 135.degree. C. and the ethylene content of the portion insoluble in p-xylene at normal temperature is 1.5-10 wt. %, with a polar monomer and an organic peroxide in an extruder, (B) up to 20 wt. % of a polyolefin rubber, and (C) 1 to 45 wt. % of a surface-treated glass fiber. This composition gives a molded article having an excellent rigidity and impact resistance.